Anavex Life Sciences Corp. (AVXL)
| Market Cap | 409.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.28M |
| Shares Out | 58.19M |
| EPS (ttm) | -0.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $6.11 |
| Previous Close | $5.75 |
| Change ($) | 0.36 |
| Change (%) | 6.26% |
| Day's Open | 5.70 |
| Day's Range | 5.68 - 6.15 |
| Day's Volume | 1,079,523 |
| 52-Week Range | 2.38 - 7.58 |
Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear t...
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu...
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q4 2020 Results - Earnings Call Transcript
Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET
Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time Conference Call and Webcast To be Held Monday, December 28th, 2020 4:30 pm Eastern Time
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu...
The company reported positive results from a phase 2 clinical trial.
Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the ...
Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I
Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Property Portfolio Issuance of Its Newest U.S. Patent Will Strengthen Anavex's Compounds Intellectual Propert...
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. M...
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu...
Statistically s ignificant improvements in CDR system Cognitive Domain of Attention assessed by Choice Reaction Time (p = 0.039) and Digital Vigilance (p = 0.008)
Anavex (AVXL) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
The biotech's drug appears to help patients with Parkinson's disease dementia.
C linically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized assessment system analysis
Anti-amyloid and anti-tau drugs only slightly slow down the progression of Alzheimer's disease because misfolded amyloid and tau proteins are only two among several factors that can trigger th...
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated thera...
Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd Annual Global Investment Conference Cantor Fitzgerald Global Healthcare Conference 2020 and H.C. Wainwright 22nd An...
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...
Conference Call and Webcast Today at 11:00 a.m. ET Conference Call and Webcast Today at 11:00 a.m. ET
Compassionate Use Special Access Scheme Approval for Alzheimer’s Patients to Continue Treatment with ANAVEX®2-73 (blarcamesine) after Completing the 5-Year ANAVEX®2-73-003 Phase 2a Clinical St...
Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time Conference Call and Webcast To be Held Thursday, August 6, 2020 11:00 am Eastern Time
Anavex Life Sciences is developing drugs for the treatment of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Rett Syndrome, fragile X, Angelman syndrome, and infantile spasms.
NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...
NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...
Does Anavex Life Sciences (AVXL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is (AVXL) Outperforming Other Medical Stocks This Year?
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...
Is (AVXL) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in Anavex Life Sciences.
NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therape...
Anavex Life Sciences (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q2 2020 Results - Earnings Call Transcript
Published in Alzheimer's & Dementia Journal, Results Highlight ANAVEX®2-73 (blarcamesine) Clinical Study, the First Reported Genome-Wide Search for Biomarkers Associated with Drug Response in ...
As of late, it has definitely been a great time to be an investor Anavex Life Sciences Corp.
In the latest trading session, Anavex Life Sciences (AVXL) closed at $2.62, marking a -0.38% move from the previous day.
Anavex 2-72 And Neurological Disorders: A Possible Path Forward
Anavex 2-73 may be a peroxynitrite scavenger and as such may help in the treatment of various neurological conditions, including Rett syndrome, multiple sclerosis, and Alzheimer's disease.
Can these soaring biotech stocks keep climbing?
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
By Harry Boxer, TheTechTrader These four stocks have strong technical momentum that could carry them higher.
Anavex Life Sciences' (AVXL) CEO Christopher Missling on Q1 2020 Results - Earnings Call Transcript
NEW YORK, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...
NEW YORK, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap...
About AVXL
Anavex Life Sciences, a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple scl... [Read more...]
| Industry Biotechnology | |
| CEO Christopher Missling | Employees 20 |
| Stock Exchange NASDAQ | Ticker Symbol AVXL |
Analyst Forecasts
According to 3 analysts, the average rating for AVXL stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 112.77% from the latest price.